Compare GSK plc (GSK) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs RLX Technology Inc — how do they compare? GSK plc trades at $50.36 (market cap $102.60B), while RLX Technology Inc trades at $2.02 (market cap $2.42B). The key difference: GSK plc is far larger — about 42.4× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.05%). Which is the better fit depends on your goals.
| GSK | RLX | |
|---|---|---|
Market Cap | $102.60B | $2.42B |
Sector | Health | Technology |
52-Week High | $61.18 | $2.73 |
52-Week Low | $38.22 | $1.79 |
Enterprise Value | $123.04B | $1.04B |
Dividend Yield | 3.57% | 5.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
RLX Technology trades at $2.02, up 1.0% today, amid bearish technical signals and mixed fundamental performance. The stock shows strong profitability with 22.47% net margins and solid cash flow generation, though recent quarterly earnings have missed expectations. International expansion remains a key growth driver, with overseas revenue now exceeding 70% of total sales following the Totally Wicked acquisition.
While RLX maintains strong fundamentals and cash reserves, the bearish technical outlook and recent earnings misses create near-term uncertainty. The company's international growth strategy offers potential upside, but regulatory risks in the vaping industry and execution challenges pose significant headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
